1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. MYASTHENIA GRAVIS TREATMENT MARKET BY APPLICATION
5.1. Introduction
5.2. Medication
5.3. Surgery
5.4. Other
6. MYASTHENIA GRAVIS TREATMENT MARKET BY END-USER
6.1. Introduction
6.2. Hospital
6.3. Clinics
6.4. Others
7. MYASTHENIA GRAVIS TREATMENT MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. By Application
7.2.2. By End User
7.2.3. By Country
7.2.3.1. United States
7.2.3.2. Canada
7.2.3.3. Mexico
7.3. South America
7.3.1. By Application
7.3.2. By End User
7.3.3. By Country
7.3.3.1. Brazil
7.3.3.2. Argentina
7.3.3.3. Others
7.4. Europe
7.4.1. By Application
7.4.2. By End User
7.4.3. By Country
7.4.3.1. Germany
7.4.3.2. Spain
7.4.3.3. United Kingdom
7.4.3.4. France
7.4.3.5. Others
7.5. Middle East and Africa
7.5.1. By Application
7.5.2. By End User
7.5.3. By Country
7.5.3.1. Saudi Arabia
7.5.3.2. South Africa
7.5.3.3. Others
7.6. Asia Pacific
7.6.1. By Application
7.6.2. By End User
7.6.3. By Country
7.6.3.1. China
7.6.3.2. Japan
7.6.3.3. Australia
7.6.3.4. India
7.6.3.5. South Korea
7.6.3.6. Indonesia
7.6.3.7. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. UCB S.A.
9.2. AstraZeneca
9.3. Johnson & Johnson
9.4. Alexion Pharmaceuticals, Inc
9.5. Argenx
9.6. Merck KGaA
9.7. F.Hoffmann-La Roche Ltd
9.8. Astellas Pharma Inc.
9.9. Bayer AG
9.10. Sanofi
9.11. Amneal Pharmaceuticals LLC.
9.12. Zydus Group
9.13. Hikma Pharmaceuticals PLC